Artelo Biosciences, Inc. (ARTL) Misses Q2 EPS by 548c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ARTL Hot Sheet
Join SI Premium – FREE
Artelo Biosciences, Inc. (NASDAQ: ARTL) reported Q2 EPS of ($5.61), $5.48 worse than the analyst estimate of ($0.13).
For earnings history and earnings-related data on Artelo Biosciences, Inc. (ARTL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi raises Keurig Dr Pepper price target to $40
- Booking Holdings (BKNG) PT Lowered to $175 at Goldman Sachs
- Latham Group, Inc. (SWIM) Misses Q3 EPS by 5c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
